Advancements in upfront treatment of ovarian cancer have resulted in improved survival outcomes, but recurrence remains an unfortunate reality for most patients. The Ovarian Cancer Moon Shot is aiming to reduce the rate of recurrence through two approaches. First, we’re developing novel drugs that leverage identified therapeutic vulnerabilities of ovarian cancer. Second, we’re identifying and evaluating rational targeted therapy combination strategies, in an effort to prevent and/or reverse the emergence of resistance. These efforts will use biopsy-rich, information drive clinical trials to monitor outcomes in real-time and guide current and future drug development efforts.